MBL producers rose from 20.4% to 48.6% of US carbapenem-resistant Enterobacterales from 2021 to 2025, while aztreonam-avibactam stayed active against 97.7% of them.
|Videos|October 17, 2017
What is the First-line Empiric Therapy for Candidemia?
Author(s)Contagion® Editorial Staff
Monica Mahoney, PharmD, BCPS-AQ ID, explains the first-line empiric therapy for candidemia.
Advertisement
Monica Mahoney, PharmD, BCPS-AQ ID, clinical pharmacy coordinator of infectious diseases at Beth Israel Deaconess Medical Center, discusses the changes the Infectious Diseases Society of America made in their candidemia guidelines. Now, regardless of immunocompromised status, IDSA recommends echinocandins as the first-line therapy for candidemia. Dr. Mahoney also explains potential reasons why this change was made.
Advertisement
Related to this article
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Investigational cefiderocol-xeruborbactam inhibited 98.5% of carbapenem-nonsusceptible Acinetobacter and nearly all Enterobacterales in global surveillance data.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Isavuconazole had a lower liver adverse event signal than voriconazole and posaconazole, while olorofim, manogepix, and rezafungin held activity against resistant molds.
Data being presented at IDWeek 2026 show zoliflodacin maintains high gonorrhea cure rates in patients co-infected with chlamydia. David Altarac, MD, discusses the therapy and the study being presented at the conference.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Zelicapavir Shortens RSV Symptoms Despite Missing Primary End Point
4
Zoliflodacin Holds Gonorrhea Cure Rates in Chlamydia Coinfected Patients
5